The store-operated Ca 21 release-activated Ca 21 (CRAC) channel is activated by diminished luminal Ca 21 levels in the endoplasmic reticulum and sarcoplasmic reticulum (SR), and constitutes one of the major Ca 21 entry pathways in various tissues. Tubular aggregates (TAs) are abnormal structures in the skeletal muscle, and although their mechanism of formation has not been clarified, altered Ca 21 homeostasis related to a disordered SR is suggested to be one of the main contributing factors. TA myopathy is a hereditary muscle disorder that is pathologically characterized by the presence of TAs. Recently, dominant mutations in the STIM1 gene, encoding a Ca 21 sensor that controls CRAC channels, have been identified to cause tubular aggregate myopathy (TAM). Here, we identified heterozygous missense mutations in the ORAI1 gene, encoding the CRAC channel itself, in three families affected by dominantly inherited TAM with hypocalcemia. Skeletal myotubes from an affected individual and HEK293 cells expressing mutated ORAI1 proteins displayed spontaneous extracellular Ca 21 entry into cells without diminishment of luminal Ca 21 or the association with STIM1. Our results indicate that STIM1-independent activation of CRAC channels induced by dominant mutations in ORAI1 cause altered Ca 21 homeostasis, resulting in TAM with hypocalcemia.
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INTRODUCTION
Calcium (Ca 2+ ) signals are crucial for controlling a broad range of cellular functions, including secretion, excitation, contraction, motility, metabolism, transcription, growth, cell division and apoptosis (1). In the striated muscle, the sarcoplasmic reticulum (SR) is a primary Ca 2+ -storage organelle, and Ca 2+ released from the SR directly activates the contraction of myofibrils via excitation -contraction coupling regulation (2) . Depletion of Ca 2+ in the SR activates a store-operated Ca 2+ entry (SOCE) pathway that is used to replenish intracellular calcium stores (3, 4) . In non-excitable cells and the skeletal muscle, SOCE is coordinated by stromal-interacting molecule 1 (STIM1), an endoplasmic reticulum (ER)/SR Ca 2+ sensor, and ORAI1, a plasma membranous calcium release-activated Ca 2+ (CRAC) channel, following Ca 2+ ion release from intracellular stores (5 -8) . Specifically, when the ER/SR Ca 2+ store is depleted, oligomerization and translocation of STIM1 to adjacent ER/ SR-plasma membrane junctions are induced (9) . Within these junctions, oligomeric STIM1 interacts with and activates ORAI1 (10 -12) .
Recessive mutations in ORAI1 are known to cause severe combined immunodeficiency (SCID, MIM 612782), which is characterized by a severe defect in T-cell activation accompanied by muscle hypotonia (13, 14) . In this disease, mutated ORAI1 leads to its deficiency in the plasma membrane resulting in loss of function of SOCE. Homozygous nonsense mutations in STIM1 also cause primary immunodeficiency (15) 
Recently, dominant missense mutations in STIM1 were revealed to cause tubular aggregate myopathy (TAM) (16) . TAM is a rare form of myopathy that can show either autosomal-dominant or -recessive inheritance (17) , and is pathologically characterized by the presence of tubular aggregates (TAs). A gain of function of mutated STIM1 due to disruption of its Ca 2+ -sensing domain was suggested as the main pathomechanism underlying STIM1related TAM. More recently, Stormorken syndrome, which is characterized by thrombocytopenia, muscle fatigue, asplenia and congenital miosis, was also reported to be caused by a gainof-function STIM1 mutation (18, 19) . Stormorken syndrome displays histological evidence of myopathy with TAs (18) . However, the mechanism underlying muscle weakness and TA formation from abnormal Ca 2+ influx has not been well established.
TAs are abnormal structures in muscle fibers that are morphologically characterized based on light and electron microscopic observations (20, 21) . TAs appear as accumulations of densely packed tubules, which are suggested to arise from the SR as they contain numerous SR proteins (21, 22) . Conceivably, the formation of TAs is triggered by some functional consequences due to disruptions in the SR-T-tubule junction, such as altered Ca 2+ homeostasis (20) . Alternatively, TAs are thought to be derived from reshaping of the SR caused by aggregation of misfolded membranous proteins (23) . TAs are also observed in certain types of muscle diseases, including periodic paralysis, congenital myasthenic syndromes, alcohol-and drug-induced myopathy and TAM (21, 22) . However, the precise mechanism of TA formation remains to be clarified.
In this study, we performed whole exome sequencing in three families suffering from genetically undiagnosed TAM and found pathogenic mutations in the ORAI1. In addition, we demonstrated STIM1-independent activation of CRAC channels in myotubes derived from an affected individual, suggesting that this abnormal activation is the basic mechanism of this disease.
RESULTS

Clinical characterization of individuals with TAM
The clinical features of the included families are listed in Table 1 and Supplementary Material, Table S1 . The common characteristic symptoms among the families were diffuse muscle weakness, marked and bilateral ankle joint contractures, rigid spine and hypocalcemia. Disease onset ranged from childhood to adolescence. Muscle weakness progressed slowly, and although all of the affected individuals were ambulant, half of them required the use of high-heeled shoes to walk correctly. All affected members in Family A and Family B showed mildly decreased serum Ca 2+ levels and relatively low intact parathyroid hormone (PTH) levels, which were still within the normal range. In computed tomography imaging of II-3a, III-2a and II-3b, paraspinal, gastrocnemius and soleus muscles were markedly replaced by fat, which might explain ankle joint contractures and rigid spine. Trapezius, latissimus dorsi, gluteus medius, hamstrings and adductor muscles in the thigh showed severe atrophy and fat infiltration ( Fig. 1 ). Affected members in Family A also showed central nervous system involvement as follows: individual II-3a showed calcification in the cerebellum, basal ganglia and cerebral corticomedullary junction; individual III-2a showed mild intellectual disability (IQ: 63, based on the Weschler Intelligence Scale for Children III). None of the included individuals showed characteristic signs of Stormorken syndrome, such as congenital miosis, bleeding diathesis and thrombocytopenia (Supplementary Material, Table S1 ).
Pathological findings
TAs were found in muscle fibers of four affected individuals (II-3a in Fig. 2 ; I-2b and II-1c in Supplementary Material, Fig. S1 ; II-1b, pictures not shown). The TAs appeared as bright red inclusions in muscle fibers following modified Gomori trichrome (mGt) staining ( Fig. 2A ) and showed high enzymatic activity following NADH-tetrazolium reductase (NADH-TR) staining ( Fig. 2B ), but were negative for succinate dehydrogenase (SDH) expression ( Fig. 2C ), reflecting characteristics of the SR but not the mitochondria. Under electron microscopy, the TAs appeared as aggregates composed of numerous straight tubules aligned in parallel in a longitudinal dimension and were arranged in a honeycomb-like structure in the transverse dimension ( Fig. 2D ). At higher magnification, each tubule showed double-walled membranes ( Fig. 2E and F). All these findings were compatible with previously reported features of TAs (20) . In addition to TAs, all biopsy samples demonstrated chronic dystrophic changes based on the presence of regenerating fibers, increased internal nuclei, fiber size variation in both type 1 and type 2 fibers and endomysial fibrosis. Type 1 fiber predominance was also observed ( Table 2) .
The ORAI1 gene is mutated in TAM-affected individuals
In order to identify the genetic cause of dominantly inherited TAM, we performed whole exome sequencing on two affected (II-3a and III-2a) and two non-affected members (I-2a and III-2a) of Family A and in all five members of Family B (I-1b, I-2b, II-1b, II-2b and II-3b) ( Fig. 3A and Supplementary Material, Table S2 ). In total, 41 variants from Family A and 34 variants from Family B were extracted based on the assumption of autosomal-dominant inheritance and with reference to the dbSNP135, the 1000 Genomes Project database, the National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server and Human Genetic Variation Database (HGVD) for Japanese genetic variants (Supplementary Material, Table S3 ). Among all extracted variants, we identified only one common variant, a heterozygous c.292G.A mutation in ORAI1 (RefSeq accession number NM_032790.3) in both families (Table 1 and Fig. 3A and Supplementary Material, Tables S4 and S5). This mutation was confirmed by Sanger sequencing in all affected members and was absent in the unaffected members (Supplementary Material, Fig. S2 ). We also found an additional heterozygous missense mutation, c.412C.T in ORAI1, in the third TAM family by Sanger sequencing ( Fig. 3A and Supplementary Material, Fig. S2 ). The mutation was not listed in dbSNP137, 1000 Genomes or HGVD. Both mutations were predicted to result in amino acid changes in the ORAI1 protein: p.Gly98Ser in the transmembrane (TM) 1 domain and p.Leu138Phe in the TM2 domain ( Fig. 3B ). The amino acid residues Gly at 98 and Leu at 138 show high evolutionary conservation (Fig. 3C ). The impact of these variations was also predicted to be damaging based on in silico analysis with SIFT and PolyPhen-2 (data not shown). The crystal structure of Drosophila Orai1 determined by Hou et al. (24) and reported in the Molecular Modeling Database (MMDB ID: 105660) ( Fig. 3D) shows that Gly98 is localized to face to the pore of the CRAC channel (white) and Leu138 is in the interface between TM1 and 2 (yellow).
Localization and expression of ORAI1 in the skeletal muscles from TAM
To analyze the localization of ORAI1 in the skeletal muscles of TAM, we investigated skeletal muscle cryosections from an individual with TAM (II-3a, II-1c) using immunohistochemistry ( Fig. 4 ). SERCA1, an SR protein, was strongly labeled in the aggregates, as previously reported (20, 21) . ORAI1 and STIM1 co-localized with SERCA1 in the aggregates. Moreover, dihydropyridine receptor (DHPR), which is present in T-tubules, was also involved in the aggregates and co-localized with ORAI1, as expected (21) ( Fig. 4) .
On western blotting, the expression levels of ORAI1, STIM1, SERCA1 and SERCA2 in the skeletal muscles from an affected individual (II-1c) were similar to that of the skeletal muscles from unaffected individuals (Supplementary Material, Fig. S3 ).
TAM cells showed constitutive extracellular Ca 21 influx via the CRAC channel without depletion of SR Ca 21 stores
To explore whether the identified mutations are pathogenic, we monitored Ca 2+ entry into myotubes prepared from muscle cells of an affected individual with the c.292G.A (p.Gly98Ser) mutation. Intracellular Ca 2+ concentration ([Ca 2+ ] i ) was monitored using Fura-2 as a Ca 2+ indicator and was recorded by using fluorescence ratiometry with excitation at 340 and 380 nm. The experiments revealed a significantly higher [Ca 2+ ] i level in TAM myotubes than in control cells [normal human skeletal muscle cells (SKMCs)] when the extracellular Ca 2+ concentration was 2 mM, which was assumed to match that of the in vivo environment, and 20 mM ( Fig. 5A and B ). Upon application of a CRAC channel inhibitor, 50 mM 2-aminoethoxydiphenyl borate [2-APB (25)] or 10 mM 3,5-bistrifluoromethyl pyrazole derivative (BTP2) (26), the [Ca 2+ ] i levels in TAM myotubes were not elevated ( Fig. 5A ). Another inhibitor, 1-[2-(4methoxyphenyl)-2-[3-(4-methoxyphenyl) ethyl-1H-imidazole hydrochloride (SKF-96365), was also effective although the response was slower. These results indicated that the higher Ca 2+ influx in TAM myotubes occurred via CRAC channels. In addition, an Mn 2+ quenching assay of intracellular Fura-2 fluorescence was performed ( Fig. 5C ). Mn 2+ is known to enter cells via CRAC channels and shows very high affinity to Fura-2. The extracellular Mn 2+ influx causes quenching of intracellular Fura-2 fluorescence. TAM myotubes showed an Mn 2+ quenching that was distinct from that of normal myotubes, implicating the activation of CRAC channels. We also examined thapsigargin (TG) treatment to TAM myotubes to induce Ca 2+ depletion in the SR. TG induced extracellular Ca 2+ influx in normal myotubes in a dose-dependent manner in extracellular 2 mM Ca 2+ medium. On the other hand, similar extracellular Ca 2+ influx levels were observed in TAM myotubes with and without TG treatment ( Fig. 5D ). Thus, TAM cells showed constitutive Ca 2+ influx to the cytosol via the CRAC channel without depletion of the SR Ca 2+ store. It should be noted that slightly higher [Ca 2+ ] i elevation was observed with higher concentrations of TG treatment ( Fig. 5D ), indicating that the store-operated Ca 2+ influx-inducing system may still function in TAM myotubes.
Gly98Ser and Leu138Phe mutations in ORAI1 caused spontaneous activation of the CRAC channel
We also tested the impact of the c.292G.A (Gly98Ser) and c.412C.T (Leu138Phe) mutations in ORAI1 on induction of spontaneous Ca 2+ influx. [Ca 2+ ] i was measured at 24 -36 h after transfection to HEK293 cells of mutated and wild-type ORAI1 cDNAs. The transfected green fluorescent protein (GFP)-tagged ORAI1 and Myc-tagged ORAI1 localized on the plasma membranes, and the mutated ORAI1 also localized to the cell surface membrane (Fig. 6A ). Western blotting of expressed ORAI1 protein showed multiple bands at 25-50 kDa, indicating the presence of different glycosylated forms, similar to previous reports (27,28) ( Fig. 6B ). Although glycosylated forms of Gly98Ser-mutated ORAI1 were slightly decreased, there were no differences in band patterns observed among Gly98Ser-mutated, Leu138Phe-mutated and wild-type (WT) ORAI1 after PNGase F treatment. The Gly98Ser and Leu138Phe ORAI1 mutants caused a dramatic elevation of [Ca 2+ ] i following application of 2 mM Ca 2+ in the medium when compared with the WT protein (2 mM Ca 2+ in Fig. 6C ). Cells transfected with the Gly98Ser or Leu138Phe mutants exhibited high levels of [Ca 2+ ] i even under conditions of extracellular Ca 2+ depletion (0 mM Ca 2+ region in Fig. 6C ). In addition, the Mn 2+ quenching assay revealed that the cells transfected with Gly98Ser or Leu138 Phe mutants showed distinct Mn 2+ quenching rates from those transfected with the WT protein ( Fig. 6D ). It should be noted that the spontaneous Ca 2+ and Mn 2+ influx observed in the mutated ORAI1-expressing cells did not require co-expression of STIM1 or TG-induced Ca 2+ store depletion in the ER. Moreover, the elevated resting [Ca 2+ ] i induced by both ORAI1 mutants was reduced by application of 2-APB (Supplementary Material, Fig. S4 ), which indicated the specific activation of CRAC channels. These results clearly demonstrate that both the c.292G.A (Gly98Ser) and c.412C.T (Leu138Phe) mutations in ORAI1 cause constitutive CRAC channel activation in a STIM1-independent manner.
DISCUSSION
Based on the inheritance mode in the affected families and the functional analyses of mutated ORAI1 proteins, we concluded that the constitutive activation of CRAC channels by dominant mutations in ORAI1 caused TAM in the three families. In support of this notion, dominant mutations in STIM1 have been reported to cause TAM by constitutive activation of SOCE (16) . In that report, the mutated STIM1 spontaneously clustered and translocated to the plasma membrane independently of Ca 2+ stores in the SR, and consequently led to activation of the CRAC channel, resulting in higher cytosolic Ca 2+ levels. More recently, Nesin et al. (18) reported that activating mutations in STIM1 and ORAI1 caused overlapping syndromes of TAM and congenital miosis. Interestingly, the authors suggested that a dominant mutation in ORAI1 caused prolonged activation of CRAC channels that required association with STIM1. On the other hand, in the present study, we showed that the two mutations in ORAI1 directly caused constitutive opening of the channel, resulting in higher cytosolic Ca 2+ influx independent of either Ca 2+ stores in the SR or STIM1 activation.
ORAI1 is a tetra-spanning TM protein in the plasma membrane ( Fig. 3C) (8) , and acts as a pore subunit of the CRAC channel (29) . The CRAC channel consists of a hexamer of ORAI1 proteins, and the TM helices (TM1 -4) of each monomer are arranged in three concentric rings. Six TM1 helices make up an inner ring of helices and line the ion pore, while the TM2 and TM3 helices constitute a middle ring that surrounds the TM1 helices (24) (Fig. 3D) . The mutation c.292G.A (Gly98Ser) was identified in the TM1 domain directly beside the pore (white residues in Fig. 3D ). The other mutation, p.412C.T (Leu138Phe), was identified in the TM2 domain directly facing TM1 (yellow residues in Fig. 3D ).
Many studies have elucidated the roles of amino acid residues in TM1 in channel activity as well as in the ion selectivity of SOCE channels (8,29 -33) . In particular, Arg91 is mutated in SCID (13) and is thought to act as both a barrier as well as a provider of electrostatic stabilization to the elongated pore that is controlled via interaction with STIM1, and Glu106 determines ion selectivity (8) (Fig. 3C) . Similarly, the importance of Gly98 for channel activity has also been suggested based on in vitro experiments (31) . Interestingly, Gly98 has been predicted to be located exactly two a-helical turns from both the Arg91 and Glu106 sites ( Fig. 3C ). Ala replacement at Gly98 results in failure of channel activity, whereas Asp or Pro replacement at this position results in a negative charge or hydrophilic properties, which in turn cause constitutive channel opening as well as reduced ion selectivity in a STIM1-independent manner (31, 33) . Our experiments revealed that a Ser replacement of Gly at position 98 may also confer the protein with a hydrophilic property that is sufficient to cause constitutive channel activation, similar to the effect of Pro replacement.
In contrast to TM1, the roles of specific amino acid residues in TM2 have not been well investigated. In our experiment, the mutation c.412C.T (p.Leu138Phe) in TM2 also caused constitutive SOCE channel activation. Interestingly, basal [Ca 2+ ] i levels in Leu138Phe-expressing HEK293 cells were lower than those were in Gly98Ser-expressing cells. Further studies are necessary to fully understand the impact of these mutations on CRAC channels.
Of particular note, the mechanism underlying the muscle weakness caused by a constitutively activated CRAC channel might be associated with altered Ca 2+ homeostasis in a manner different from that derived from its loss of function. Individuals affected with SCID owing to recessive loss-of-function mutations in ORAI1 or STIM1 were reported to show muscle hypotonia (13) (14) (15) and decreased Ca 2+ influx. Transgenic mice with muscle-specific expression of dominant-negative Orai1 have also been reported and exhibited reduced body weight, muscle mass and fiber cross-sectional area, and increased susceptibility to fatigue, which might have been due to SR Ca 2+ depletion (34) . On the other hand, ORAI1-related TAM is caused by elevation of [Ca 2+ ] i levels in the skeletal muscle cells, similar to STIM1-related TAM. Therefore, preventing excessive extracellular Ca 2+ influx is a potential therapeutic strategy for TAM.
The mechanism of TA formation in the skeletal muscle has remained elusive thus far. However, our results support the hypothesis that TA formation is related to disordered Ca 2+ homeostasis. Recent efforts on the identification of causative genes in TA-presenting muscle diseases also provide a clue into this mechanism. Recessive mutations in GFPT1 and DPAGT1, which are both involved in protein N-glycosylation, have been shown to be causative factors of myasthenic syndrome with TAs (35, 36) . Furthermore, the functional importance of N-glycosyl modification of STIM1 was recently reported (27) . A mutation at the N-glycosylation site in STIM1 results in a strong gain of function by increasing the number of active Orai1 channels, indicating the significance of N-glycosylation for the function of STIM. Thus, activation of CRAC channels may result in the formation of TAs in skeletal muscles, although further analyses of CRAC channel activation in skeletal muscles of GFPT1-and DPAGT1-mutated individuals are required to confirm this hypothesis.
The finding of c.292G.A (p.Gly98Ser) ORAI1 mutation in two unrelated families would not be due to a founder effect.
This mutation in Family A probably occurred de novo in II-3a because individual I-1a did not show any symptoms of myopathy in his lifetime and individual I-2a does not have the mutation. Regarding to the mutation in Family B, we could not judge whether it is de novo or not, because of limited information.
The clinical and histological features of ORAI1-mutated TAM are similar to those of TAM caused by STIM1 mutations, regarding onset of the disease, progression of weakness, involvement of contractures, presence of TAs in both type I and type II fibers, fiber size variation and type I fiber predominance. However, the patterns of affected muscles are slightly different: individuals with ORAI1-mutated TAM exhibit diffuse weakness in all limbs, and the characteristic patterns in the selectivity of atrophy, whereas those with STIM1-mutated TAM show proximal muscle weakness only in the lower limbs (16) . Severe ankle contractures and a rigid spine were common characteristics observed in the families included in the present study, although STIM1-mutated TAM was not likely. Furthermore, eye-movement defects, which were reported in STIM1-mutated TAM individuals studied by Böhm et al. (16) , congenital miosis, bleeding diathesis and thrombocytopenia are not detected in individuals with ORAI1-mutated TAM. This discrepancy could be explained by differences in the expression patterns of STIM1, ORAI1 and their homologues (ORAI2, ORAI3 and STIM2).
Although ORAI1 transcripts are expressed in multiple tissues, including the skeletal muscle, in humans and mice (28, 37) , it is not clear why other organs were saved. Orai1 expression is low in the brain (28) ; therefore, the intellectual disability observed in individual III-2a in the present study might be unrelated to the ORAI1 mutation. The calcification in the brain of individual II-3a could be attributed to long-term hypocalcemia.
Another characteristic clinical feature of ORAI1-mutated TAM is hypocalcemia. Serum Ca 2+ levels are controlled mainly through the action of PTH and 1,25(OH)2D3 (38) . These hormones increase the serum Ca 2+ level through their actions on the bone, kidney and intestine; impaired activity of either hormone leads to hypocalcemia. In this study, the five individuals analyzed showed mildly decreased serum Ca 2+ levels and rather low PTH levels, which were nonetheless within the normal range. PTH is secreted by parathyroid cells and the secretion volume is controlled by the extracellular Ca 2+ intensity. In ORAI1-mutated TAM individuals, PTH levels are improperly low in spite of the presence of hypocalcemia. This condition is classified as PTH-insufficient hypoparathyroidism on the basis of the criteria for the differential diagnosis of hypocalcemia NI, no information. (39) . Although the precise pathomechanisms are not known, ORAI1-mutated TAM might cause decreased PTH secretion.
In summary, we identified heterozygous missense mutations in ORAI1 that cause TAM with hypocalcemia via constitutive activation of CRAC channels. Our results, together with those of previous reports (16, 19) , will contribute to establishing a new disease entity whose pathomechanism is associated with intracellular Ca 2+ elevation to induce muscle weakness and TA formation in the skeletal muscles. The detailed pathomechanism linking intracellular Ca 2+ elevation to muscle weakness and TA formation in the skeletal muscles should be clarified.
MATERIALS AND METHODS
Materials
Three unrelated Japanese families affected by TAM were selected based on pathological examinations. All clinical . This structure shows that the channel is formed from a hexamer of ORAI subunits. Each subunit is represented in a different color. The ion pore is located at the center of the channel (red circle), and the transmembrane helices are arranged in three concentric rings. Six TM1 helices (1) make up an inner ring of helices and line the ion pore. The TM2 (2) and TM3 (3) helices constitute a middle ring that surrounds the transmembrane portion of the TM1 helices and separates them from TM4 helices (4), which are arranged in an outer ring. The position of Gly98 in TM1 is highlighted in white, and that of Leu138 in TM2 is highlighted in yellow. materials used in this study were obtained with written informed consent for research use. All experiments performed in this study were approved by the Ethical Committee of the National Center of Neurology and Psychiatry (NCNP).
Histological analyses
Muscle samples were taken from the biceps brachii. Muscles were frozen in liquid nitrogen-cooled isopentane and stored at 2808C. Serial frozen sections (10 mm thick) were histochemically stained with mGt, NADH-TR or SDH. Immunohistochemistry was performed using 8 mm thick serial frozen sections according to the standard protocols (40) . The primary antibodies used were as follows: anti-Orai1 (O8264, 1:200 dilution; Sigma-Aldrich), anti-STIM1 (H-180, 1:50; Santa Cruz Biotechnology), anti-SERCA1 (VE121G9, 1:200; Abcam), anti-RYR1 (XA7B6, 1:200; Developmental Studies Hybridoma Bank) and anti-DHPR (IIID5E1, 1:100; Developmental Studies Hybridoma Bank). Anti-caveolin antibody (N-18, 1:100; Santa Cruz Biotechnology) was also used for labeling the sarcolemma (plasma membrane of the muscle fiber). After incubation with primary antibodies, the sections were incubated with appropriate Alexa Fluor 488-, 568-and 647-conjugated secondary antibodies (1:600; Invitrogen). The sections were observed under an LSM710 confocal laser microscope (Carl Zeiss).
Electron microscopy
Muscle specimens were fixed in 2.5% glutaraldehyde and postfixed with 2% osmium tetroxide. Ultrathin sections of muscles stained with uranyl acetate and lead citrate were observed under a transmission electron microscope (FEI; Hillsboro, OR, USA).
Exome sequencing
Genomic DNA was isolated from muscle specimens or peripheral blood lymphocytes using standard techniques. Exome sequencing was carried out in subjects I-2a, II-3a, III-1a and III-2a from Family A, and in subjects I-1b, I-2b, II-1b, II-2b and II-3b from Family B. Exons of genomic DNA samples were captured and sequenced using Agilent in-solution enrichment methodology and the Illumina HiSeq1000 sequencer. Briefly, 3 mg of each genomic DNA sample was fragmented to 150-200 bp by sonication. Paired-end fragment libraries were prepared by using a kit from Agilent Technologies. Purified libraries (750 ng) were hybridized to the SureSelect oligonucleotide probe capture library for 24 h (Sure Select Human All Exon kit V4, 50 Mb; Agilent). The captured DNA sample was then sequenced on an Illumina HiSeq1000 as paired-end 100-base reads. Image analysis and base calling were performed using 
Bioinformatics analysis
Reads were aligned to hg19 with Burrows-Wheeler Aligner (41) . Duplicate reads were removed using Picard for downstream analysis. Local realignments around indels and regions for low base quality scores were performed with the Genome Analysis Toolkit (42) (GATK) for recalibration. Single-nucleotide variants and small indels were identified using GATK UnifiedGenotyper (version 1.6) and filtered according to the Broad Institute's best-practice guidelines. Genetic variation was annotated with the NCNP in-house pipeline (amelief), consisting of gene annotation [using ANNOVAR (43) ] and detection of known polymorphisms using dbSNP135, the 1000 Genomes, NHLBI Exome Variant Server (ESP5400) and HGVD for Japanese genetic variants. Candidates of mutations identified in exome sequencing were validated by Sanger sequencing on an ABI Prism 3130 DNA Analyzer (Applied Biosystems). Segregation analysis of within-family variants was carried out using the primer sets designed to amplify exons corresponding to the sequence under accession NM_032790. PCR conditions and primer sequences for ORAI1 mutation analysis are available upon request.
Western blotting of the skeletal muscles
Frozen skeletal muscles were sliced and suspended in the buffer containing 10 mM Tris-HCl, 0.6 mM KCl and 1 mM EDTA. After a centrifugation at 1200g for 10 min, the supernant was centrifuged at 20 000g for 90 min. The resulting pellet was solubilized in laemmli's sample buffer. An equal amount of proteins (10 mg) were electrophoresed on 4 -20% polyacrylamide gradient gel (Bio-Rad). The primary antibodies used were as follows: anti-Orai1 (O8264, 1:1000 dilution; Sigma-Aldrich), anti-STIM1 (H-180, 1:500; Santa Cruz Biotechnology), anti-SERCA1 (VE121G9, 1:1000; Abcam) and anti-caveolin-3 antibody (Clone 26, 1:1000; BD Transduction Laboratories). The blots were coupled with the peroxidase-conjugated secondary antibodies, and developed using the ECL detection kit (Millipore Corporation). 
Construction of ORAI1 mutants
The construction of WT and mutant human ORAI1 cDNA in the expression vectors pCMV-Myc and pEGFP-N1 (Clontech) was described previously (44) . A Myc tag was fused to the N-terminus of ORAI1, and a EGFP tag was fused to the C-terminus of ORAI1 without its termination codon. All ORAI1 mutants were generated with the Quick Change Site-Directed Mutagenesis Kit (Stratagene). Information on primer sequences and conditions for cloning and PCR is available upon request.
Transfection of ORAI1 constructs to HEK293 cells
HEK293 cells obtained from the RIKEN Bioresource Center were maintained in Dulbecco's modified Eagle medium (D-MEM; Wako) supplemented with 10% fetal bovine serum (FBS; Life Technologies), 2 mM glutamine, 30 units/ml penicillin and 30 mg/ml streptomycin. ORAI1 constructs were transfected using X-tremeGENE9 (Roche Applied Science). For observation of ORAI1 mutants in cells, EGFP-tagged ORAI1 constructs were also introduces. For western blots, Myc-tagged ORAI1 constructs were introduced. For [Ca 2+ ] i measurement, Myc-tagged ORAI1 constructs were co-transfected with the pDsRed-Monomer-C1 vector (Clontech).
Localization of ORAI1 protein in HEK293 cells
Confocal and phase contrast images were taken at 2 days posttransfection on an LSM-710 microscope (Carl Zeiss).
Expression of ORAI1 protein in HEK293 cells
HEK293 cells were harvested at 2 days post-transfection. The cells were lysed with Tris-buffered saline containing 1% Triton X-100 and protease inhibitors (cOmplete EDTA-free; Roche). The extracts were boiled in the presence of sodium dodecyl sulfate sample buffer and subjected to western blot analysis. An equal amount of the supernatant fractions (75 mg proteins) was subjected to SDS-PAGE (SuperSep Ace, 5-20% gradient gel, Wako). The protein-transferred membrane was incubated with anti-Myc antibody (9E10, 1:2000; Wako). After incubating with anti-mouse IgG (H+L) secondary antibody conjugated with horseradish peroxidase (GE Healthcare), the expression of ORAI1-Myc was detected using Immunostar Zeta (Wako). To confirm glycosylated patterns of ORAI1, lysate samples (75 mg each) were incubated with PNGase F (Roche; 3 U/sample), for 6 h at 378C and subjected to SDS-PAGE.
Cell culture for [Ca 21 ] i measurement and Mn 21 quenching assay
Skeletal muscle cells of a TAM-affected individual (II-3b) and normal human SKMCs (Clonetics) were seeded onto collagen-coated glass cover slips and cultured in D-MEM/Ham's F-12 medium (1:1) supplemented with 20% FBS (Invitrogen), 100 units/ml penicillin and 100 mg/ml streptomycin. After the cells reached confluence, the culture media were switched to differentiation media [D-MEM/Ham's F-12 Medium (1:1) (C) Cytosolic Ca 2+ was measured in HEK293 cells expressing WT ORAI1 (black, n ¼ 35 cells) and ORAI1 mutants, Gly98Ser (red, n ¼ 28 cells) or Leu138Phe (blue, n ¼ 37 cells) and vector (gray, n ¼ 32 cells). Extracellular solution was first changed to 0 mM Ca 2+ (0Ca) then to 2 mM Ca 2+ (2Ca). (D) Mn 2+ quenching assay. After application of 0.1 mM Mn 2+ solution, fluorescence quenching of Fura-2 was observed in HEK293 cells expressing WT ORAI1 (black, n ¼ 34 cells) and ORAI1 mutants, G98S (red, n ¼ 42 cells) or L138F (blue, n ¼ 43 cells), and vector (gray, n ¼ 46 cells).
supplemented with 5% horse serum (Invitrogen), 100 units/ml penicillin and 100 mg/ml streptomycin]. Six days following induction of differentiation, myotubes were used for [Ca 2+ ] i imaging or a Mn 2+ quenching assay.
Transfected HEK293 cells were lifted using trypsin and seeded onto poly-L-lysine-coated glass cover slips at 8 h posttransfection. Note that trypsinized cells were cultured in low-Ca 2+ D-MEM (Life Technologies), which was supplemented with 10% FBS, 2 mM glutamine, 30 units/ml penicillin, 30 mg/ml streptomycin, 0.2 mM CaCl 2 and 10 mM La 3+ , to prevent Ca 2+ overload-induced cell death (31) . [Ca 2+ ] i imaging was performed at 24-36 h after transfection.
Measurement of changes in [Ca 21 ] i
HEK293 cells on cover slips were loaded with Fura-2 by incubation in low-Ca 2+ D-MEM containing 5 mM Fura-2/AM (Dojindo Laboratories) at 378C for 40 min, and washed with imaging solution (2Ca). The cover slips were then placed in a perfusion chamber mounted on the stage of a microscope (Axio-observer Z1; Carl Zeiss). Transfected cells were identified by detection of fluorescence from pDsRed-Monomer. Fura-2 fluorescence images of the cells were recorded and analyzed with Physiology software (Carl Zeiss). The 340/380 nm ratios of images were recorded at 10 s intervals. The compositions of [Ca 2+ ] i imaging solutions are listed in Supplementary Material, Table S6 . Fura-2/AM was loaded into skeletal myotubes on cover slips in the same manner used for HEK293 cells but in nominally Ca 2+ -free HEPES-buffered saline (HBS) (Supplementary Material, Table S6 ). The cover slips were then placed in a perfusion chamber mounted on the stage of the microscope (IX70; Olympus). Fura-2 fluorescence images of the myotubes were recorded and analyzed with MetaMorph Imaging Software (Molecular Devices). The images were recorded at 20 s intervals. Compositions of [Ca 2+ ] i imaging solutions are listed in Supplementary Material, Table S6 . For measurement of the resting [Ca 2+ ] i , Fura-2/AM was loaded to myotubes at 0Ca and 2Ca, respectively, and [Ca 2+ ] i imaging was performed. The resting [Ca 2+ ] i was calculated as previously reported (45) .
Mn 21 quenching assay
Extracellular Mn 2+ entry was measured through monitoring the decline in the fluorescence intensity of Fura-2 at an isosbestic excitation wavelength of 360 nm and recording the emitted fluorescence at 510 nm (46) by using the same system as used for the [Ca 2+ ] i measurement. The compositions of nominally Ca 2+ -free HBS and 0.1 mM MnCl 2 solutions are listed in Supplementary Material, Table S6 .
Statistical analysis
Graphics were prepared and statistical analyses were performed with GraphPad Prism (GraphPad Software). Data are presented as mean + SEM. All data were analyzed using unpaired t-tests in comparisons between two samples and ANOVA in comparisons among three samples. On western blotting, the expression levels of ORAI1, STIM1, SERCA1, and SERCA2 in the skeletal muscles from an affected individual (II-1c) were similar to that of the skeletal muscles from unaffected individuals (Fig. S3 ). Figure S4 . Cytosolic Ca 2+ measurement in HEK cells.
Cytosolic Ca 2+ was measured in HEK293 cells expressing WT ORAI1 (black, n = 50 cells) and ORAI1 mutants, Gly98Ser (red, n = 31 cells) or Leu138Phe (blue, n = 37 cells), and vector (gray, n = 54 cells). Myc-tagged ORAI1 constructs were co-transfected with the pEGF-C2 vector (Clontech). 
